Cambridge Cancer Genomics
CCG builds precision oncology solutions for all patients. Our technology can detect relapse earlier than standard of care, predict response to therapy more accurately & reduce ineffective treatment regimens. We give your oncologist the head start they need to stay ahead of an evolving tumor.
Ultimately, we will ensure that each patient has the right treatment, at the right time, to beat their cancer.
Nirmesh PatelCo-Founder & CSO
ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The company is focusing on developing novel medicines for specialist indications with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and over 70 patents. Forigerimod (P140 or Lupuzor™) is the company’s most advanced drug candidate for autoimmune diseases and is an immunomodulator, not an immunosuppressant. Lupuzor ™ received "Fast Track" designation from the US FDA and has recently completed a Phase III trial.
Forigerimod is a first-in-class peptide drug modulating autophagy.
ImmuPharma is based in London, U.K. and has three subsidiaries in France and one in Switzerland.
Dimitri DimitriouChief Executive Officer
LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA) ™.
Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology, and robotics. We use advanced deep-learning neural networks to explore protein fitness landscapes and improve multiple drug properties simultaneously.
We are a London-based, privately-owned company, backed by top-tier venture capital funds.
Sabin MínguezBusiness Development and Innovation Manager
Mereo BioPharma Group plc
WORKING TOGETHER TO INSPIRE, INNOVATE AND IMPROVE LIVES
Our mission is to provide new therapies to patients with chronically debilitating and life limiting rare diseases that have few, if any, other treatment options.
Our goal is to build an international biopharmaceutical company developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications.
Our clinical-stage, rare disease assets originated in pharmaceutical or biotechnology companies where for strategic reasons they were not being progressed. With the streamlined efficiency of a small company and with our internal expertise and external resources we are able to rapidly progress the products into late stage development and the planned subsequent commercialization.
Donald CoppenDirector of Corporate Development
Pascal VennManager, Corporate Development
We aim to improve the health and quality of life of patients by creating high value therapeutics addressing global unmet medical needs.
Mironid® is a vibrant, growing, customer-centric company with an outstanding team motivated to deliver innovative new medicines.Our mission is to become a world leader in cell signalling directed therapeutic development.Mironid® is currently building and progressing a pipeline of early stage drug discovery programmes that are initially targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of therapeutic indications.
Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was spun out of University College London, a top 20 global university and was founded to commercialise the Molecular Envelope Technology (MET) developed in the UK academic sector. Nanomerics’ MET enables the transport of drugs across key biological epithelial barriers and this allows Nanomerics to create uniquely differentiated products, underpinned by high quality science. Nanomerics’ MET recently won first prize in the prestigious Royal Society of Chemistry Emerging Technologies competition.
Nanomerics has out-licensed NM127, an enkephalin-based pain asset to Virpax Pharmaceuticals and NM133, a dry-eye asset to Iacta Pharmaceuticals. Both of these assets are powered by Nanomerics’ MET. Nanomerics has a pipeline of assets that have the potential to offer significant patient benefit. Nanomerics is committed to a world where patients receive the best medicines possible for their conditions.
Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.
Through our recent acquisition of Protagen AG, Oncimmune has expanded its service offering in profiling autoantibodies for the characterisation and prediction of response and adverse events in immuno-oncology and autoimmune diseases.
Mike FisherCommercial Director
Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets.The high level of detail allows us to reveal new biology and identify first-in-class non-intuitive drug targets. We initially focused our modelling efforts on E.coli identifying 4 first-in-class antibacterial drug targets and generated active chemical matter against 3 of them. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (ERK and DNA Damage pathways) and inflammation (cGAS-STING).
Our Business model is to establish:
· Partnerships with Pharma/Biotechs who would like Oppilotech to model pathways they are working on
· Partnerships with Pharma/Biotech who would like access to targets generated from in-house modelling of pathways
· Partnership with Pharma/Biotechs who would like access to early stage drug development programmes developed by Oppilotech on targets identified in-house
· Partnerships on our antibacterial programmes
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people.
Andrew LewinVP, Business Development Manufacturing
Aurelie CharpentierManager, Business Development
Jeremy HarropVP, Business Development Product Licensing
OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.